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Abstract
Background: Ketamine is a commonly used clinical anesthetic and a popular recreational drug. However, with the
exception of studies about the nervous system, studies about the effect of early ketamine exposure on embryos
are rare. Xenopus laevis is a commonly used vertebrate model for assessing teratogenicity. Therefore, we treated
Xenopus embryos with ketamine to evaluate its teratogenicity on embryos.
Methods: Xenopus embryos were treated with ketamine from stages 8 to 21. Embryonic and cardiac morphology
were analyzed using living embryo imaging and whole-mount RNA in situ hybridization (WMISH). Heart function
was measured by heart rate and ventricular shortening fraction (VSF). The mRNA expression levels of several heart
development-related genes were determined by reverse transcription quantitative polymerase chain reaction
(RT-qPCR). The protein expression levels of XMLC2, phospho-histone H3 (pH3) and histone H3 were determined
by western blot.
Results: Ketamine caused concentration-dependent increases in mortality and shortening of body length. At a
dose of 0.5 mg/ml, ketamine exposure resulted in cardiac enlargement as the primary manifestation of several
malformations: gut defects, a curved axis and shortened body length. Cardiac cells underwent increased
proliferation. Moreover, the heart rate and ventricular shortening fraction were decreased, findings indicative
of heart dysfunction. XMLC2 expression levels were down-regulated at stages 28, 32/33, 35/36 and 46.
Conclusions: Ketamine exposure during early development has teratogenic effects on Xenopus embryos. The
heart enlargement and decreased VSF may result from the down-regulation of XMLC2 mRNA and protein
levels. These findings provide new insight into the potential fetal defects induced by ketamine exposure
during early pregnancy.
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Background
Ketamine, a non-competitive inhibitor of N-methyl-D-
aspartate (NMDA) receptors, is widely used for sedation,
analgesia, and the induction and maintenance of
anesthesia in humans, particularly in pediatric patients
[1, 2]. Moreover, as a hallucinogenic agent, ketamine is
increasingly used for non-medical purposes and is one
of the most popular “club drugs” [3]. Epidemiological
data indicate that 30 % of ketamine abusers are female
[4] and are often less than 27 years of age [5], which is
childbearing age. Therefore, it is of great significance to
study the effect of ketamine exposure during pregnancy
on embryonic development. However, clinical data re-
garding its effect on fetuses are rare. Previous studies
using animal models to investigate the effects of keta-
mine on embryogenesis have focused primarily on
neurological issues during either the late embryonic
period or the neonatal period [6–9]. Herein, we exam-
ined the impact of ketamine exposure during early em-
bryonic development.
Xenopus is a commonly used vertebrate model for
studying embryonic development mechanisms and drug
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teratogenicity [10]. It produces massive eggs, and the
transparency of tadpoles facilitates the detection of in-
ternal organization defects. More importantly, Xenopus
is similar to humans in terms of organ development,
physiology and gene expression [11]. Therefore, we used
Xenopus to investigate the teratogenic effects of early
ketamine exposure on embryos in this study.
Methods
Animals
Studies with Xenopus laevis were approved by the local
ethics committee (Chongqing Medical University,
Chongqing, China). X. laevis were maintained in a recir-
culating system at 21 ± 1 °C with a 12-h light–dark cycle.
Fertilization was stimulated by the administration of hu-
man chorionic gonadotropin (HCG).
Embryo treatments
Fertilized oocytes were washed in 2 % L-Cysteine
(pH 8.0) to remove the jelly coat. Xenopus laevis em-
bryos were collected and staged according to Nieuwkoop
and Faber [12].
Experiments were conducted in 0.3× Modified Barth’s
Saline (MBS, 88 mM NaCl, 1 mM KCl, 0.7 mM CaCl2,
1 mM MgSO4, 2.5 mM NaHCO3, and 5 mM HEPES,
pH 7.8). Working solutions of ketamine (Sigma, St
Louis, MO, USA; cat.no.K2753) were dissolved in 0.3 ×
MBS, and the treatment was administered at various
concentrations from stage 8 (before the gastrula stage)
to stage 21 (complete neural tube closure). After treat-
ment, the embryos were transferred to 0.3× MBS and
cultured in six-well plates at 21 °C; each well contained
10 embryos in 5 ml of 0.3× MBS. The solution and drug
were changed every 24 h. Each treatment group was
tested 3 separate times.
Live embryo imaging
After inducing anesthesia with tricaine mesylate for
1 min, the embryos at stage 46 were immediately re-
corded using a stereo fluorescence microscope Stereo
Lumar V12 (Zeiss, Germany) and photographed in dia-
stole upon reaching the end diastolic volume using an
SMZ 1500 (Nikon, Japan) at 10× magnification for the
whole embryos and at 60× magnification for the heart
region. Embryo body lengths were measured three times
using Image J software (ver 1.47, Bethesda, MD), and the
averages were analyzed.
Heart rate and ventricular contractility analysis
After inducing anesthesia for 1 min, the embryos at
stage 46 were randomly selected for heart rate counts.
Ventricular beats were counted for 1 min. At least three
measurements were obtained, and the average was used
for statistical analysis.
Cardiac contractions were recorded with Stereo Lumar
V12. The lengths of ventricles in diastolic and systolic
conditions were measured to calculate the ventricular
shortening fraction (VSF) [13, 14]: VSF = (ventricular
length at diastole–ventricular length at systole)/ventricu-
lar length at diastole.
Whole-mount RNA in situ hybridization (WMISH)
Digoxigenin (DIG)-labeled antisense RNA probes for
XNkx2.5, XTnIc and XMLC2 were constructed based on
previous research [15], and WMISH was performed as
previously described [16]. Embryos were imaged using a
Nikon SMZ 1500 stereomicroscope at 60× magnification
for the heart region.
RNA isolation and reverse transcription quantitative
polymerase chain reaction (RT-qPCR)
Total RNA was extracted from ten whole embryos or
hearts per experimental condition using TRIzol Reagent
(Invitrogen, Grand Island, NY) according to the manu-
facturer’s instructions. cDNA synthesis was conducted
using a PrimeScript RT Reagent Kit (Takara, Otsu,
Shiga, Japan). RT-qPCR was performed in triplicate
using 10-fold diluted cDNA and a SYBR Green I kit
(Tiangen, Beijing, China) on a CFX96 real-time PCR
machine. The following primers were used for RT-qPCR:
XNkx2.5: forward 5′-GGC TAC CAC CTC CAA GAC
G-3′, reverse 5′-GTT GGA GTG GGC AGG GTA AG-3′;
XTnIc: forward 5′-TGA ATC CAC TGG GGC TGT
TG-3′, reverse 5′-AGA GTA ACG GCC TTC GAA
CA-3′;
MHC-alpha: forward 5′-TCA AGG CTG GTT TGT
TGG GT-3′, reverse 5′-AAC CAG AAG GGC ATC
TCT GC-3′;
XMLC2: forward 5′-GCG CAA TGG TCT TGC TCT
TC-3′, reverse 5′-GAG ATC GTG GAG GGC AAA
GT-3′;
GAPDH: forward 5′-TAG TTG GCG TGA ACC ATG
AG-3′, reverse 5′-GCC AAA GTT GTC GTT GAT
GA-3′.
The primers for gata4 and gata6b were used as de-
scribed [15].
The PCR cycling conditions were as follows: 1 cycle at
95 °C for 3 min, 39 cycles at 95 °C for 10 s and 60 °C for
30 s. GAPDH mRNA was used as an endogenous control.
The relative quantification was calculated using the 2-△△ct
method.
Western blot analysis
Protein was extracted from ten whole embryos or 200
embryonic hearts per experimental condition, and west-
ern blotting was performed using standard procedures.
Monoclonal mouse anti-human MLC2 from Novus
(Littleton, CO; cat. no. NBP1-30249), polyclonal rabbit
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anti-human histone H3 from proteintech (Chicago, IL;
cat. no. 17168-1-AP) and polyclonal rabbit anti-rat
GAPDH from EnoGene (Nanjing, Jiangsu, China; cat.
no.E12-052) were diluted by 1:2000. Polyclonal rabbit
anti-human pH3 from Santa Cruz Biotechnology (Dallas,
Texas; cat. no.sc-8656-R) was diluted by 1:500. GAPDH
was applied as an internal reference. Immunoreactive
bands were quantified by densitometry using ImageJ.
Statistical analysis
SPSS Statistics version 17.0 (Chicago, IL, USA) was used
for statistical analysis. Comparisons among different
concentration groups were made by one-way ANOVA.
Comparisons between two groups were conducted using
either unpaired t-tests or chi-square tests for different
data. P-values <0.05 were considered statistically
significant.
All experiments were repeated at least 3 times.
Results
Ketamine induces embryonic malformations
Xenopus embryos were exposed to ketamine from stage
8 to stage 21. When the embryos developed to stage 46,
we counted embryonic mortality within each ketamine-
treated group. The result demonstrated that as the ex-
posure concentration increased, the mortality rate also
increased (Fig. 1a). Ketamine concentrations of 0.125,
0.5 and 2 mg/ml were chosen to observe the embryonic
phenotype. It demonstrated that with increasing keta-
mine concentrations, body lengths gradually shortened
(P < 0.05), hearts enlarged, and curved body axis was
found at high concentrations (Fig. 1b-c).
The numbers of deaths and malformations in the three
ketamine-treated groups were analyzed (Table 1). It
Fig. 1 The effect of ketamine on embryos at stage 46. a Mortality rate of increasing concentrations of ketamine (0.1, 0.125, 0.25, 0.5, 1, 2, 5, 10,
25 mg/ml). b Malformations at three exposure concentrations of ketamine (0.125, 0.5, 2 mg/ml). Hearts are marked by white punctiform curves.
The arrowhead indicates a curved axis. Scale bar = 100 μm. c Comparison of body lengths at three exposure concentrations. aP < 0.05 vs. control
group; bP < 0.05 vs. 0.125 mg/ml ketamine-treated group; cP < 0.05 vs. 0.5 mg/ml ketamine-treated group. The data represent the means ± SD
Table 1 The effect of ketamine at three concentrations on embryonic death and malformation
Control Ketamine (mg/ml)
0.125 0.5 2
Death 17 (9.44 %) 16 (8.89 %) 29b (16.11 %) 52a,c (28.89 %)
Malformation 4 (2.45 %) 117a (71.34 %) 129a,b (85.43 %) 108a (84.38 %)
Total 180 180 180 180
aP < 0.05 vs. control group; bP < 0.05 vs. 0.125 mg/ml ketamine-treated group; cP < 0.05 vs. 0.5 mg/ml ketamine-treated group
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demonstrated that after exposure to 0.5 mg/ml keta-
mine, the embryonic malformation rate was significantly
increased compared with the specimens exposed to
0.125 mg/ml (P < 0.05), whereas the death rate was sig-
nificantly decreased compared with the specimens ex-
posed to 2 mg/ml (P < 0.05). Moreover, a ketamine
concentration of 0.5 mg/ml did not affect the embryonic
death rate (P > 0.05). Thus, we chose this concentration
for subsequent experiments.
Ketamine predominantly causes cardiac enlargement
After exposure to 0.5 mg/ml ketamine, no significant
differences in mortality were found between the control
and ketamine-treated embryos at stage 46 (Table 2).
However, it caused heart defects (82.12 %), gut defects
(4.64 %), a curved axis (19.87 %) and a shortened body
Table 2 Characteristics of ketamine-treated embryos
(0.5 mg/ml) at stage 46
Characteristic Control Ketamine (0.5 mg/ml)
Mortality 17 (9.44 %) 29 (16.11 %)
Heart defects 3 (1.84 %) 124* (82.12 %)
Enlarged 2 (1.23 %) 116* (76.82 %)
Undefined 1 (0.61 %) 8* (5.30 %)
Gut defects 1 (0.61 %) 7* (4.64 %)
Curved axis 3 (1.84 %) 30* (19.87 %)
Small head 0 (0.00) 1 (0.66 %)
Body length (mm) 10.53 ± 0.20 8.86 ± 0.86*
Total embryos 180 180
Note that one embryo can have various malformations. All malformations
were individually counted and analyzed. The body length values are expressed
as the means ± SD. *P < 0.05
Fig. 2 The effect of ketamine on cardiac morphology. a-h Embryos at stage 46. a-b Live embryos. c-h Whole-mount RNA in situ hybridization
(WMISH) analysis of the heart-specific gene XNkx2.5 and myocardium-specific genes XTnIc and XMLC2. i The dissected hearts from embryos at
stage 46. oft, outflow tract; a, atria; v, ventricle. j-o WMISH analysis of XMLC2 at stage 28, 32/33 and 35/36. Scale bar = 20 μm
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length (8.86 ± 0.86 mm). Therefore, heart defects were
the most commonly observed phenotype in the
ketamine-treated embryos compared with the controls
(82.12 versus 1.84 %), and heart enlargement (76.82 %)
was the primary malformation (Table 2). The heart size
of the ketamine-treated embryos was increased com-
pared with the control embryos as determined via living
embryo imaging, WMISH for the heart and myocar-
dium, and the dissection of the heart tissues at four
stages (stage 28, 32/33, 35/36 and 46) from heart tube
formation to heart maturity (Fig. 2).
Because of the remarkable heart defects, we subse-
quently investigated the specific effect of ketamine on
heart during embryonic development.
Ketamine increases cardiac cell proliferation
We dissected out the heart tissues to detect cell prolifera-
tion using western blot. The mitosis marker phospho-
histone H3 (pH3) was used as a marker of cell proliferation.
The results showed that after ketamine exposure, pH3 ex-
pression level was significantly up-regulated (P < 0.05),
while histone H3 expression level showed no significant dif-
ference in those two groups (Fig. 3), suggesting that keta-
mine increased cardiac cell proliferation.
Ketamine results in embryonic heart dysfunction
To investigate the effect of ketamine exposure on car-
diac function, we determined the embryonic heart rate
and recorded cardiac impulse to calculate the VSF via
stereo microscopy at stage 46 (see Additional files 1 and
2). The results demonstrated that the heart rates in the
control and ketamine-treated groups were 169.96 ±
5.25 bpm and 130.82 ± 4.87 bpm, respectively (Fig. 4a),
and the VSFs in the two groups were (12.72 ± 3.25)%
and (4.56 ± 1.33)%, respectively (Fig. 4b). Thus, both the
heart rate and VSF in the ketamine-treated group were
significantly decreased compared with the control group,
indicating that ketamine exposure affects embryonic
heart function.
Ketamine down-regulates XMLC2 expression
We firstly anesthetized the embryos at stage 46 and dis-
sected out the heart regions under a microscope. The
dissected tissues were subsequently used to detect the
mRNA expression levels of several heart development-
related genes using RT-qPCR. In the dissected tissues,
the expression levels of XNkx2.5 and XTnIc were signifi-
cantly higher than that in the whole embryos and the
remaining carcasses (P < 0.05) (Fig. 5a), confirming that
Fig. 3 The effect of ketamine on cardiac cell proliferation. a Phospho-histone H3 (pH3) and histone H3 protein levels. b Quantitation of the levels
of pH3 and histone H3 protein shown in (a). The data are expressed as the means ± SD
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the dissected tissues were hearts. Then, we examined the
mRNA expression levels of XNkx2.5, XTnIc, MHC-
alpha, gata4, gata6b and XMLC2 in these tissues
(Fig. 5b). The data indicated that only XMLC2 mRNA
was decreased in the ketamine-treated group (P < 0.05),
whereas the other gene expression levels showed no sig-
nificant difference in the two groups. Furthermore, we
examined XMLC2 mRNA expression during three early
stages of heart development (Fig. 5c). The expression
levels were all significantly decreased in the ketamine-
treated group (P < 0.05), which were consistent with the
results observed at stage 46. We then detected XMLC2
protein expression using western blot at four stages. The
result demonstrated that the expression levels were all
down-regulated in the ketamine-treated groups (Fig. 5d-e).
Discussion
We studied cardiac morphology, cardiac function and
the expression of genes associated with heart develop-
ment after ketamine exposure primarily at stage 46. Be-
cause at this stage, the Xenopus embryonic heart has
matured [17]. Furthermore, there are three key stages
for heart development: stage 28, heart tube formation;
stage 32/33, contractile myocardial tube formation and
looping initiation; and stage 35/36, obvious heart looping
[18, 19]. Therefore, we chose these three stages to inves-
tigate the effect of ketamine exposure on early embry-
onic cardiomyogenesis.
Thus far, reports on the effects of early embryonic ex-
posure to ketamine on organs or systems other than the
nervous system are rare. An in vivo research demon-
strated that ketamine exposure during the early develop-
ment of zebrafish embryos caused concentration-
dependent increases in anomalies and mortality; the
most prominent deformities were enlarged organs and
tail/spine anomalies [20], which is consistent with the
results of our study. Additionally, we found that the
shortening of embryonic body length is also in
concentration-dependent manners.
At a dose of 0.5 mg/ml, the ketamine-treated embryos
exhibited several malformations. However, the most
prominent phenotype was an enlarged heart. Moreover,
the cardiac cells underwent significantly increased prolif-
eration. Our results also showed that at each detected
stage of heart development, from heart tube formation
to heart maturity, XMLC2 mRNA and protein expres-
sion levels were significantly down-regulated after keta-
mine exposure. It has been reported that MLC2, myosin
regulatory light chain 2, is essential for normal myocar-
dium development [21]. A defect of MLC2 gene results
in myocardial malformations [21], and missense muta-
tions of MLC2 in humans lead to hypertrophic cardio-
myopathy [22, 23], resulting in heart enlargement and
decreased cardiac contractility. In addition, deletion of
MLC2 in mice results in cardiac enlargement [24].
Therefore, the cardiac enlargement phenotype caused by
ketamine may result from the down-regulation of
XMLC2 mRNA and protein levels.
Furthermore, our results showed that VSF, a sensi-
tive indicator of cardiac contractility, sharply de-
creased after ketamine treatment. It has been reported
that MLC2 protein has a function in the maintenance
of cardiac contractility. Deletion of MLC2 causes a re-
duced left ventricular ejection fraction and abnormal-
ities in myofibril assembly in embryonic mice, and
Fig. 4 The effect of ketamine on heart function. a Comparison of
the heart rate (beats per minute) in the control and ketamine-
treated embryos. n = 10. *P < 0.05. b Comparison of ventricular
shortening fraction (VSF) in the control and ketamine-treated
embryos. n = 6. *P < 0.05. The data are expressed as the means ± SD
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results in death due to cardiac dysfunction at E12.5
[24]. Additionally, knockdown of MLC2 in chick em-
bryos results in poorly developed sarcomeres [25]. Be-
cause the sarcomere is the basic contractile unit,
sarcomere structural abnormalities affect cardiac con-
tractility. Therefore, the weakened cardiac contractility
may be due to reduced expression levels of XMLC2
mRNA and protein.
Ketamine has been reported to reduce heart rates in
pregnant and infant monkeys [26], as well as newborn
human infants [27]. During zebrafish embryogenesis,
ketamine exposure at both 26 and 52 h post-
fertilization results in a reduced heart rate [28], which
is consistent with our results. Therefore, the results of
heart rate and ventricular shortening fraction demon-
strate that ketamine causes embryonic cardiac
dysfunction.
Conclusions
Ketamine exposure from stage 8 to stage 21 results in
concentration-dependent increases in anomalies and
mortality. After 0.5 mg/ml ketamine exposure, the most
prominent malformation is heart enlargement. Besides,
the decrease of heart rate and VSF indicates heart
dysfunction. The enlarged heart and decreased VSF may
result from the down-regulation of XMLC2 mRNA and
protein levels. These findings provide insight into the
potential fetal defects and mechanism of ketamine
Fig. 5 The effect of ketamine on heart development-related gene expression. a The mRNA levels of heart-specific genes XNkx2.5 and XTnIc in
whole embryos, carcasses and dissected tissues at stage 46. *P < 0.05, #P < 0.05. b The mRNA levels of heart development-related genes, XNkx2.5,
XTnIc, MHC-alpha, gata4, gata6b and XMLC2 in dissected tissues at stage 46. *P < 0.05. c XMLC2 mRNA levels at stage 28, 32/33 and 35/36. d
XMLC2 protein levels at stage 28, 32/33, 35/36 and 46. e Quantitation of the levels of XMLC2 protein shown in D. The data are expressed as the
means ± SD. Con control, K ketamine, st stage
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exposure. However, additional studies are required to
evaluate the potential risk during very early pregnancy in
mammals.
Additional files
Additional file 1: Movie of control embryo. Control embryo at stage 46,
showing heart with rhythmic and strong contractions. 60× magnification.
(MOV 7950 kb)
Additional file 2: Movie of ketamine-treated embryo. Note that the
heart size is bigger and heart rate is slower than control embryo. The
amplitude of heart beat is decreased. 60× magnification. (MOV 5408 kb)
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